secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2026-05-11T13:01:36+00:00
Accession:  0001104659-26-058332
Event type: other_material
Sentiment:  positive
Materiality: 0.30
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MetaVia DA-1726 late-breaking abstract accepted for EASL 2026 poster; Phase 1 data expected Q4
--------------------------------------------------------------------------------

- Abstract LB26-5204 on DA-1726 (GLP-1/glucagon dual agonist) accepted for poster at EASL Congress 2026 in Barcelona (May 27-30).
- Poster title: Safety, Tolerability, PK, PD of DA-1726 in higher-dose Phase 1 cohort with exploratory liver assessment.
- Phase 1 Part 3 titration study ongoing; optimizing higher dose levels and tolerability; data expected Q4 2026.
- Presenting author: Chris Fang, CMO; poster available on MetaVia website after presentation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000110465926058332/0001104659-26-058332-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000110465926058332/mtva-20260511x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-058332

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer